Definition of Treatment-Resistant Schizophrenia
The term
treatment-resistant schizophrenia (TRS) is not applied simply because a patient still has symptoms while taking medication. It is a specific operational definition used to identify individuals who are appropriate candidates for clozapine. The threshold is
failure of at least two adequate trials of different antipsychotic medications, meaning each trial must have used a sufficient dose for a sufficient duration without meaningful clinical improvement
[1].
Key point! The word “adequate” is essential. A trial is not counted as failed if the dose was too low, the duration was too short, or the patient did not actually take the medication as prescribed. In this scenario, the patient has persistent hallucinations despite antipsychotic treatment taken as prescribed, which suggests genuine non-response rather than non-adherence.
What Counts as an Adequate Trial?
A review and recommendation by Suzuki and colleagues proposed that an adequate trial should involve a
chlorpromazine-equivalent dose of at least 600 mg/day for at least 6 consecutive weeks [1]. This provides a concrete benchmark: a patient who received a low-dose antipsychotic for two weeks and then stopped would not meet the definition of having had an adequate trial. The two failed trials must also involve
different antipsychotics, since failure of two courses of the same drug could reflect a drug-specific issue rather than general treatment resistance
[1].
| Component | Requirement for an Adequate Trial |
|---|
| Number of failed trials | At least two |
| Medication difference | Different antipsychotics |
| Dose benchmark | Chlorpromazine-equivalent 600 mg/day or more |
| Duration benchmark | At least 6 consecutive weeks |
| Assessment basis | Inadequate response of positive symptoms, often measured by PANSS |
Watch out! The definition does not require three trials, nor does it require that one of the trials be a long-acting injectable. While a long-acting injectable can be useful to rule out covert non-adherence, it is not a formal requirement in the TRS definition
[1]. Likewise, failure of only one adequate trial is insufficient to label a patient as treatment-resistant.
Why This Threshold Matters for Clozapine Use
Clozapine is the only antipsychotic with established superiority for TRS, but it carries significant risks, including
agranulocytosis, which requires mandatory hematologic monitoring . Because of this risk–benefit profile, clozapine is reserved for patients who have demonstrated non-response to at least two other adequate antipsychotic trials. This conservative threshold prevents unnecessary exposure to clozapine’s serious adverse effects in patients who might still respond to a second conventional antipsychotic .
In the scenario, the patient’s baseline
ANC of 1.2 × 10⁹/L is below the typical reference range, but hematology has confirmed
benign ethnic neutropenia. This distinction is clinically important because benign ethnic neutropenia is not a contraindication to clozapine; rather, it requires adjusted monitoring thresholds. The fact that the patient smokes
20 cigarettes per day is also relevant, as polycyclic aromatic hydrocarbons in cigarette smoke induce CYP1A2, the primary enzyme metabolizing clozapine, which can substantially lower clozapine plasma levels and necessitate dose adjustment. These contextual details reinforce that clozapine initiation is a serious clinical decision undertaken only after confirming the patient meets the TRS definition of two failed adequate trials
[1].
The correct answer is therefore
2. At least two adequate trials. This aligns with the consensus definition that TRS requires failure of two adequate trials with different antipsychotics, each given at an adequate dose and duration
[1].
References (research sources)
- [1]
Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.GuidelineSuzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A (2012) · DOI: 10.1016/j.psychres.2012.02.013